NKGen Biotech is conducting numerous clinical trials to discover how natural killer (NK) cells can help patients with neurodegenerative disease and cancer.

SNK01, NKGen Biotech’s autologous NK cell therapy candidate, has active and planned clinical trials in several therapeutic areas, including oncology and neurodegeneration. This approach allows us to evaluate the potential benefits of adoptive cellular immunotherapy for multiple biologically relevant disease areas. Phase 1 clinical trials are in progress for SNK01 (autologous NK cell therapy) and SNK02 (allogeneic NK cell therapy).